Key result
Directly infused low-dose streptokinase achieved patency in all 3 patients with axillary vein thrombosis without complications or marked systemic effects.
Why the study?
Does low-dose streptokinase infused directly into the involved vein improve patency in patients with axillary vein thrombosis?
Case Report (n=3)
Does low-dose streptokinase infused directly into the involved vein improve patency in patients with axillary vein thrombosis?
Directly infused low-dose streptokinase successfully achieved vein patency in a small series of patients with axillary vein thrombosis without systemic complications.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for direct low-dose streptokinase in axillary vein thrombosis; prospective trials needed before clinical adoption.
Three patients with venographically proven axillary vein thromboses were treated with low-dose streptokinase infused directly into the involved vein. These veins had been occluded from twelve hours to three weeks. No complications and no marked systemic effects occurred. Patency was achieved in all three patients. Directly infused, low-dose streptokinase may provide an alternative to treatment with heparin and may eliminate the sequela of chronic venous thrombosis.
No takes yet. Share an insight, caveat, or question.
Collier et al. (1984) conducted a case report in Axillary vein thrombosis (n=3). Low-dose streptokinase was evaluated on Patency. Directly infused low-dose streptokinase achieved patency in all 3 patients with axillary vein thrombosis without complications or marked systemic effects.
Synapse has enriched 10 related papers. Consider them for comparative context: